Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

The Next Generation

Thomas Rohrer at Lonza highlights the advantages of antibody drug conjugates, but cautions that these highly potent biopharmaceuticals present a series of unique manufacturing challenges due to their potency and the raw material supply chain.

Thomas Rohrer, Lonza (June 2013)

Keywords: Antibody drug conjugate (ADC) Monoclonal antibody (mAb) Cytotoxin Maximum acceptable carryover (MAC) calculation

    View full article    |    Back to Manufacturing section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |